Study wrapper · #164
Long-term effects of weight-reducing drugs in people with hypertension.
Editor's note
This is a Cochrane systematic review — the highest methodological tier — updating evidence on long-term weight-management drugs in people with essential hypertension (8 RCTs, ~13,000 participants). Its central finding is a gap: for the newest agents, semaglutide and tirzepatide, no results were reported for the review's critical outcomes (mortality, cardiovascular morbidity, serious adverse events) in hypertensive patients specifically. Older drugs showed mixed signals — orlistat probably increased serious adverse events; several agents increased overall adverse events — mostly at low or very low GRADE certainty. The honest conclusion is that evidence remains insufficient to judge whether pharmacological weight loss reduces death or cardiovascular events in people with hypertension. For tirzepatide this is a useful corrective: despite strong weight data, trial reporting has not isolated hypertensive subgroups for hard outcomes. Weigh it as a rigorous map of what we still don't know, and a call for disaggregated trial reporting.
Plain-language abstract
This Cochrane review — a highly rigorous type of evidence summary — examined whether long-term weight-loss medications help people who have high blood pressure, looking at outcomes like death, heart problems, and side effects. It included eight randomised trials with about 13,000 people, covering older drugs (orlistat, phentermine/topiramate, naltrexone/bupropion) and two newer ones, semaglutide and tirzepatide. A key finding was how little we know: for semaglutide and tirzepatide, the trials did not report results on death, heart complications, or serious side effects for people with high blood pressure specifically. Among older drugs, orlistat probably increased serious side effects, and some drugs increased side effects overall, but much of this evidence was low or very low certainty. Most trials were funded by drug makers. The authors conclude there is not enough evidence to say whether these medications reduce the risk of death or heart problems in people with high blood pressure, and they call for trials to report results separately for this group.